The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in Children
Open accessAbstract
IMPORTANCE: Type 1 diabetes usually has a preclinical phase identified by circulating islet autoantibodies, but the rate of progression to diabetes after seroconversion to islet autoantibodies is uncertain. OBJECTIVE: To determine the rate of progression to diabetes after islet autoantibody seroconversion. DESIGN, SETTING, AND PARTICIPANTS: Data were pooled from prospective cohort studies performed in Colorado (recruitment, 1993-2006), Finland (recruitment, 1994-2009), and Germany (recruitment, 1989-2006) examining children genetically at risk for type 1 diabetes for the development of insulin autoantibodies, glutamic acid decarboxylase 65 (GAD65) autoantibodies, insulinoma antigen 2 (IA2) autoantibodies, and diabetes. Participants were all children recruited and followed up in the 3 studies (Colorado, 1962; Finland, 8597; Germany, 2818). Follow-up assessment in each study was concluded by July 2012. MAIN OUTCOMES AND MEASURES: The primary analysis was the diagnosis of type 1 diabetes in children with 2 or more autoantibodies. The secondary analysis was the diagnosis of type 1 diabetes in children with 1 autoantibody or no autoantibodies. RESULTS: Progression to type 1 diabetes at 10-year follow-up after islet autoantibody seroconversion in 585 children with multiple islet autoantibodies was 69.7% (95% CI, 65.1%-74.3%), and in 474 children with a single islet autoantibody was 14.5% (95% CI, 10.3%-18.7%). Risk of diabetes in children who had no islet autoantibodies was 0.4% (95% CI, 0.2%-0.6%) by the age of 15 years. Progression to type 1 diabetes in the children with multiple islet autoantibodies was faster for children who had islet autoantibody seroconversion younger than age 3 years (hazard ratio [HR], 1.65 [95% CI, 1.30-2.09; P < .001]; 10-year risk, 74.9% [95% CI, 69.7%-80.1%]) vs children 3 years or older (60.9% [95% CI, 51.5%-70.3%]); for children with the human leukocyte antigen (HLA) genotype DR3/DR4-DQ8 (HR, 1.35 [95% CI, 1.09-1.68; P = .007]; 10-year risk, 76.6% [95% CI, 69.2%-84%]) vs other HLA genotypes (66.2% [95% CI, 60.2%-72.2%]); and for girls (HR, 1.28 [95% CI, 1.04-1.58; P = .02];10-year risk, 74.8% [95% CI, 68.0%-81.6%]) vs boys (65.7% [95% CI, 59.3%-72.1%]). CONCLUSIONS AND RELEVANCE: The majority of children at risk of type 1 diabetes who had multiple islet autoantibody seroconversion progressed to diabetes over the next 15 years. Future prevention studies should focus on this high-risk population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The presence of multiple islet autoantibodies (IAA, GADA, IA-2A/IA-2bA, or ZnT8A) is associated with a risk of type 1 diabetes of >90% (408,422,423).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most people with a single autoantibody do not progress to type 1 diabetes, but seroconversion to the presence of two or more serum autoantibodies in children is associated with an 84% risk of clinical type 1 diabetes by the age of 18 years (figure 2A).16”
From Type 1 diabetes (2018) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Because of the low prevalence of type 1 diabetes (approximately 0.3% in the general population), the positive predictive value of a single islet autoantibody is low (408).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most individuals without diabetes who have only one autoantibody will not develop type 1 diabetes, as the 10-year risk is about 15% (408).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is clear from prospective studies that the persistent presence of two or more islet autoantibodies is a nearcertain predictor of clinical diabetes (42).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [42]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of the 585 children who developed more than two autoantibodies, nearly 70% developed type 1 diabetes within 10 years and 84% within 15 years (42).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is clear from prospective studies that the persistent presence of two or more islet autoantibodies is a near-certain predictor of clinical diabetes (40).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of the 585 children who developed more than two autoantibodies, nearly 70% developed type 1 diabetes within 10 years and 84% within 15 years (40).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [40]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A seminal analysis of four different birth cohorts from the USA, Finland and Germany demonstrated that the presence of a single islet autoantibody is associated with a 13% risk of developing type 1 diabetes over 15 years. In contrast, having two or more antibodies is associated with a 70% risk over 10 years of observation and an 84% risk over 15 years63.”
From 100 years of insulin: celebrating the past, present and future of diabetes therapy (2021) · cites this paper as [63]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, studies of the offspring of people with diabetes show that young children with multiple autoantibodies develop diabetes during childhood [ 12 ]”
From Islet autoantibody profiles associated with higher diabetes risk in Lithuanian compared with English schoolchildren (2020) · cites this paper as [12]
The cited source says what the claim attributes to it.
In the citing paper
“In children with only one persistent islet autoantibody, the risk of diabetes within 10 years is 15% while two or more islet autoantibodies predict type 1 diabetes in 70% within 10 years (408,409).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [408]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eisenbarth (1986) · doi:10.1056/nejm198605223142106 · Cited by 1,659
Self-citationEffects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836
Ziegler, A., Hummel, M., Schenker, M., & Bonifacio, E. E. (1999) · Diabetes · doi:10.2337/diabetes.48.3.460 · Cited by 640
Self-citationGale, E. A. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15786-3 · Cited by 534
Rewers, M., Bugawan, T. L., Norris, J. M., Blair, A., Beaty, B., Hoffman, M., McDuffie, R. S., Hamman, R. F., Klingensmith, G., Eisenbarth, G. S., et al. (1996) · Diabetologia · doi:10.1007/s001250050514 · Cited by 422
Self-citationNäntö-Salonen, K., Kupila, A., Simell, S., Siljander, H., Salonsaari, T., Hekkala, A., Korhonen, S., Erkkola, R., Sipilä, J. I., Haavisto, L., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61309-4 · Cited by 382
Self-citationQuantification of islet-cell antibodies and prediction of insulin-dependent diabetes
Bonifacio, E. E., Shattock, M., Dean, B. M., Bottazzo, G. F., Bingley, P. J., Gale, E., & Dunger, D. B. (1990) · The Lancet · doi:10.1016/0140-6736(90)90013-u · Cited by 344
Self-citationStratification of Type 1 Diabetes Risk on the Basis of Islet Autoantibody Characteristics
Achenbach, P., Warncke, K., Reiter, J., Naserke, H. E., Williams, A. J. K., Bingley, P. J., Bonifacio, E. E., & Ziegler, A. (2004) · Diabetes · doi:10.2337/diabetes.53.2.384 · Cited by 276
Self-citationOrban, T., Sosenko, J. M., Cuthbertson, D., Krischer, J. P., Skyler, J. S., Jackson, R., Yu, L., Palmer, J. P., Schatz, D., Eisenbarth, G., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0934 · Cited by 260
Self-citationPREDICTING INSULIN-DEPENDENT DIABETES
Tarn, A., Dean, B., Schwarz, G., Thomas, J. M., Ingram, D., Bottazzo, G. F., & Gale, E. M. (1988) · The Lancet · doi:10.1016/s0140-6736(88)91601-7 · Cited by 260
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,001
Dudaev, A., Studneva, М., Aitken, R. J., Blokh, S., Miller, A. D., Tanasova, S., Ryals, J. A., Borchers, C. H., Nordstrom, A., Moiseyakh, M., et al. (2022) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2022.02.004 · Cited by 5
Computation of Transcriptional Networks of Circulating Immune Cells in Type 1 Diabetes
Ochsner, S. A., Pillich, R., Rawool, D., Grethe, J. S., & McKenna, N. J. (2022) · iScience · doi:10.1016/j.isci.2022.104581 · Cited by 5
Lorenzo, B. D., Pacillo, L., Milardi, G., Jofra, T., Cesare, S. D., Gerosa, J., Marzinotto, I., Zapparoli, E., Rivalta, B., Cifaldi, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952715 · Cited by 5
Carrera, P., Marzinotto, I., Bonfanti, R., Massimino, L., Calzavara, S., Favellato, Μ., Jofra, T., Giglio, V. D., Bonura, C., Stabilini, A., et al. (2023) · Diabetologia · doi:10.1007/s00125-022-05865-5 · Cited by 5
Atapattu, N., Amoroso, M., Powell, M. J., de Silva, D. G. H., de Silva, K. S. H., Furmaniak, J., Smith, B. R., & Premawardhana, L. D. K. E. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1028285 · Cited by 5
Peltonen, E. J., Veijola, R., Ilonen, J., Knip, M., Niinikoski, H., Toppari, J., Virtanen, H. E., Virtanen, S. M., Peltonen, J., & Nevalainen, J. (2023) · European Journal of Epidemiology · doi:10.1007/s10654-023-01002-7 · Cited by 5
Self-citationPauley, M., Henscheid, N., David, S. E., Karpen, S. R., Romero, K., & Podichetty, J. T. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2976 · Cited by 6
Achenbach, P., Berner, R., Bonifacio, E. E., Brämswig, S., Braig, S., Dunstheimer, D., Ermer, U., Ewald, D., Gemulla, G., Hauer, J., et al. (2024) · Das Gesundheitswesen · doi:10.1055/a-2320-2859 · Cited by 8
Self-citationCarry, P. M., Vanderlinden, L. A., Johnson, R. K., Buckner, T., Steck, A. K., Kechris, K. J., Yang, I. V., Fingerlin, T. E., Fiehn, O., Rewers, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1345494 · Cited by 5
Self-citationImmunomodulatory agents and cell therapy for patients with type 1 diabetes
Rodacki, M., Silva, K. R., Araújo, D. B., Dantas, J. R., Ramos, M. E. N., Zajdenverg, L., & Baptista, L. S. (2024) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-4292-2024-0233 · Cited by 5
Doran, T. M., Morimoto, J., Simanski, S., McEnaney, P. J., & Kodadek, T. J. (2015) · Molecular BioSystems · doi:10.1039/c5mb00521c · Cited by 5
Is It Time to Screen the General Population for Type 1 Diabetes?
Simmons, K. M., & Michels, A. W. (2015) · US Endocrinology · doi:10.17925/use.2015.11.1.10 · Cited by 7
Pandemic Influenza A H1N1 Vaccination and Subsequent Risk of Type 1 Diabetes in Norway
Ruiz, P. L., Stene, L. C., Gulseth, H. L., Tapia, G., Trogstad, L., Bakken, I. J., & Håberg, S. E. (2017) · Epidemiology · doi:10.1097/ede.0000000000000748 · Cited by 5
Microbiota derived factors as drivers of type 1 diabetes
Tillett, B. J., & Hamilton‐Williams, E. E. (2020) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2020.04.008 · Cited by 5
Martinez, M. M., Spiliopoulos, L., Salami, F., Agardh, D., Toppari, J., Lernmark, Å., Kero, J. T., Veijola, R., Tossavainen, P. H., Palmu, S. A., et al. (2021) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-021-00135-6 · Cited by 5
Self-citationProumen, R., & Acharya, R. (2021) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2021.115026 · Cited by 6
Salami, F., Spiliopoulos, L., Maziarz, M., Lundgren, M., Brundin, C., Bennet, R., Hillman, M., Törn, C., & Larsson, H. E. (2022) · Journal of Immunology Research · doi:10.1155/2022/3532685 · Cited by 5
Teplizumab – preventative approaches to type 1 diabetes mellitus
Seewoodhary, J., & Silveira, A. (2023) · Practical Diabetes · doi:10.1002/pdi.2448 · Cited by 6
Thorsen, S. U., Pipper, C. B., Johannesen, J., Mortensen, H. B., Pociot, F., & Svensson, J. (2017) · Scandinavian Journal of Immunology · doi:10.1111/sji.12632 · Cited by 5
Bilal, M., AL-Zobaei, M., & Al-Ani, Z. R. (2019) · Egyptian Academic Journal of Biological Sciences. G, Microbiology · doi:10.21608/eajbsg.2019.25575 · Cited by 5
Alshiekh, S., Larsson, H. E., Ivarsson, S. A., & Lernmark, Å. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch10 · Cited by 5
Epidemiology of Type 1 Diabetes
Stene, L. C., & Tuomilehto, J. O. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch4 · Cited by 6
Optimizing Type 1 Diabetes Screening in People With Family History: A German Perspective
Danne, T., Kapellen, T. M., Widholz, S. A., Wabitsch, M., & Ziegler, R. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251383911 · Cited by 4
A 20-year study of autoimmune polyendocrine syndrome type II and III in Taiwan
Tseng, H.-H., Lin, Y., Lin, K., Lin, C., Li, H., Chang, C., Tung, Y., Chen, P., Wang, C., Yang, W., et al. (2023) · European Thyroid Journal · doi:10.1530/etj-23-0162 · Cited by 5
Jamiołkowska‐Sztabkowska, M., Noiszewska, K., Polkowska, A., Zasim, A., Trzebuchowski, S., Głowińska‐Olszewska, B., Anikiej, K., Nesterowicz, M., Skorupska, M., Bossowski, F., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16560 · Cited by 5
A Historical and Epistemological Review of Type 1 Diabetes Mellitus
Cavalli, E., Nicoletti, G. R. P., & Nicoletti, F. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14144923 · Cited by 6
Sassi, G., Lemaître, P., Calvo, L. F., Lodi, F., Calabuig, Á. C., Bissenova, S., Wouters, A., Degroote, L., Viaene, M., Vandamme, N., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci176403 · Cited by 5
Köger, M., Winkler, C., Hummel, S., Weiß, A., Koutangni, T., Yates, M., Bonnemaire, M., Guenther, O., ZACCAI, J. H., & Ziegler, A. (2025) · Diabetes Care · doi:10.2337/dc25-1021 · Cited by 5
Self-citationWu, L., Wentworth, J. M., Liddle, C., Fewings, N., Carlino, M. S., Brown, D. A., Clifton-Bligh, R. J., Long, G. V., Scolyer, R. A., Norris, N., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci192938 · Cited by 5
Biradar, R., Ullah, U., Lönnberg, T., Junttila, S., Tomi, S., Norman, S. Z., Starskaia, I., Paulin, N., Mikkola, L., Vaarala, O., et al. (2025) · Genome Medicine · doi:10.1186/s13073-025-01574-x · Cited by 5
Self-citationScreening for diabetes mellitus type 1 in the pediatric general population: an ethical analysis
Lechsner, P., Holl, R. W., & Steger, F. (2026) · European Journal of Pediatrics · doi:10.1007/s00431-026-06832-7 · Cited by 4
Svärd, A. A., Kaur, S., Trôst, K., Suvitaival, T., Lernmark, Å., Maziarz, M., Pociot, F., Overgaard, A. J., & The DiPiS Study Group (2020) · Metabolomics · doi:10.1007/s11306-020-01730-x · Cited by 4
Tolerance to Proinsulin-1 Reduces Autoimmune Diabetes in NOD Mice
Jhala, G., Selck, C., Chee, J., Kwong, C. J., Pappas, E. G., Thomas, H., Kay, T., & Krishnamurthy, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.645817 · Cited by 4
Vera, F., Jofré, P., Rodríguez, D., Lagos, R., Quiroga, T., Grassi, B. A., & Felipe Pollak, C. (2021) · Revista médica de Chile · doi:10.4067/s0034-98872021000300330 · Cited by 4
Understanding the Mechanism of Diabetes Mellitus in a LRBA-Deficient Patient
Hawari, I., Ericsson, J., Kabeer, B. S. A., Chaussabel, D., Al-Sulaiti, A. M., Sharari, S., Maccalli, C., Khan, F. A., & Hussain, K. (2022) · Biology · doi:10.3390/biology11040612 · Cited by 4
Svärd, A. A., Benatti, E., Lundgren, M., Lernmark, Å., Maziarz, M., Larsson, H. E., & the Diabetes Prediction in Skåne Study Group (2022) · ImmunoHorizons · doi:10.4049/immunohorizons.2200039 · Cited by 4
Association of CTLA-4 (+49A/G) gene Polymorphism with type 1 diabetes mellitus in Iraqi children
Isawi, H. R. A., Safi, F., & Muhammed, H. A. (2022) · Cellular and Molecular Biology · doi:10.14715/cmb/2022.68.5.1 · Cited by 4
Kawasaki, E., Jinnouchi, H., Maeda, Y., Okada, A., Ito, Y., & Kawai, K. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14038 · Cited by 4
Tandel, D., Hinton, B., Cortez, F. D. J., Seftel, D., Robinson, P. V., & Tsai, C. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1340436 · Cited by 4
The Latest Trends in the Management of Type 1 and Type 2 Diabetes Mellitus
DeClue, C. E., Gonzalez, M., Bradley, A. B., Leon, B. G. C., & Srivastava, G. (2024) · Endocrines · doi:10.3390/endocrines5040041 · Cited by 6
Dia-B-Ties: B Cells in the Islet–Immune-Cell Interface in T1D
Hilliard, B. K., Prendergast, J. E., & Smith, M. J. (2025) · Biomolecules · doi:10.3390/biom15030332 · Cited by 5
Guvenc, F., & Danska, J. S. (2025) · Current Opinion in Immunology · doi:10.1016/j.coi.2025.102553 · Cited by 4
Saunders, D. C., Feng, F., Hopkirk, A. L., Aamodt, K. I., Hart, N. J., Pan, F. C., Reihsmann, C. V., Izmaylov, N., Mei, S., Sherrod, B. A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73854-y · Cited by 2
Zhao, L. P., Carlsson, A., Larsson, H. E., Forsander, G., Ivarsson, S. A., Kockum, I. S., Ludvigsson, J., Marcus, C., Persson, M., Samuelsson, U., et al. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2921 · Cited by 4
Teasing Diabetes Apart, One Locus at a Time
Leslie, R. D., & Grant, S. F. A. (2018) · Diabetes Care · doi:10.2337/dci17-0046 · Cited by 4
Segovia-Gamboa, N. C., Rodríguez-Arellano, M. E., Muñoz-Solís, A., Retana-Jiménez, J. E., Vargas‐Ayala, G., Granados, J., Sánchez, M. J., & Sánchez‐Torres, C. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1241-9 · Cited by 4
Salami, F., Tamura, R., Larsson, H. E., Lernmark, Å., Törn, C., & the TEDDY Study Group (2021) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.251 · Cited by 5
Obesity 2021: Current Clinical Management of a Chronic, Serious Disease
Kushner (2021) · The Journal of Family Practice · doi:10.12788/jfp.0221 · Cited by 6
Type 1 Diabetes in Children With Genetic Risk May Be Predicted Very Early With a Blood miRNA
Suomi, T., Ullah, U., Rasool, O., Laiho, A., Kallionpää, H., Vähä-Mäkilä, M., Nurmio, M., Mykkänen, J., Härkönen, T., Hyöty, H., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2120 · Cited by 4
Self-citationArresting type 1 diabetes: are we there yet? Obstacles and opportunities
Mathieu, C., & Martens, P.-J. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.16 · Cited by 4
Type 1 Diabetes Screening and Diagnosis
Gomez, P., & Sanchez, J. E. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.09.008 · Cited by 4
Dietary Components in the Pathogenesis and Prevention of Type 1 Diabetes in Children
Neuman, V., Plachý, L., Průhová, Š., & Šumnı́k, Z. (2024) · Hormone Research in Paediatrics · doi:10.1159/000539575 · Cited by 4
Батурин, В. А., Bykov, J., Ивановна, М. Г., & Uglova, T. (2016) · Medical news of the North Caucasus · doi:10.14300/mnnc.2016.11003 · Cited by 4
Challenges to Reshape the Future of Type 1 Diabetes Research
Bleich, D., & Wagner, D. H. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00568 · Cited by 4
The Dynamic Origins of Type 1 Diabetes
Leslie, R. D., & Grant, S. F. A. (2018) · Diabetes Care · doi:10.2337/dci18-0034 · Cited by 4
Prevention of type 1 diabetes: where we are and where we are going
Frontino, G., GUERCIO, N. S., SCARAMUZZA, A., D’ANNUNZIO, G., Toni, S., CITRINITI, F., & Bonfanti, R. (2021) · Minerva Pediatrics · doi:10.23736/s2724-5276.21.06529-0 · Cited by 4
Screening for Autoantibodies in Type 1 Diabetes: A Call to Action
Петерс (2021) · The Journal of Family Practice · doi:10.12788/jfp.0223 · Cited by 7
Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter
Neu, A., Bürger-Büsing, J., Danne, T., Dost, A., Holder, M., Holl, R. W., Holterhus, P., Kapellen, T. M., Karges, B., Kordonouri, O., et al. (2021) · Der Diabetologe · doi:10.1007/s11428-021-00769-1 · Cited by 4
Inflammatory Pathways Linked to Beta Cell Demise in Diabetes
Imai, Y., Morris, M. A., Dobrian, A. D., Taylor, D., & Nadler, J. L. (2014) · Springer eBooks · doi:10.1007/978-94-007-6884-0_30-2 · Cited by 4
Arneth, B. M. (2017) · Endocrine Connections · doi:10.1530/ec-17-0230 · Cited by 4
Lind, A., Lynch, K. F., Lundgren, M., Lernmark, Å., Almgren, P., Ramelius, A., Puustinen, L., Hyöty, H., & Lundstig, A. (2018) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2018.02.004 · Cited by 5
Früherkennung des Typ-1-Diabetes in der Fr1da-Studie
Winkler, C., Kick, K., Haupt, F., & Assfalg, R. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0336-9 · Cited by 4
Self-citationFrüherkennung und Primärprävention des Typ-1-Diabetes
Ziegler, A., Ohli, J., Hoefs, T., Aydin, S., Falk, C., & Gross, J. (2018) · Der Diabetologe · doi:10.1007/s11428-018-0337-8 · Cited by 4
Self-citationMartinez, M. M., Salami, F., Larsson, H. E., Toppari, J., Lernmark, Å., Kero, J. T., Veijola, R., Koskenniemi, J. J., Tossavainen, P. H., Lundgren, M., et al. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.198 · Cited by 4
Self-citationLernmark, Å. (2013) · Diabetologia · doi:10.1007/s00125-013-3041-7 · Cited by 4
High-Throughput Screening in General Population for Type 1 Diabetes
Zhao, Z., & Yu, L. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0324 · Cited by 4
Schallenberg, S., & Kretschmer, K. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2017.12.14 · Cited by 4
Circulating Metabolites in Progression to Islet Autoimmunity and Type 1 DiabetesPreprint
Lamichhane, S., Kemppainen, E., Trôst, K., Siljander, H., Hyöty, H., Ilonen, J., Toppari, J., Veijola, R., Hyötyläinen, T., Knip, M., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/496943 · Cited by 4
Self-citationDefinition, Klassifikation und Diagnostik des Diabetes mellitus
Petersmann, A., Müller‐Wieland, D., Müller, U., Landgraf, R., Nauck, M. A., Freckmann, G., Heinemann, L., & Schleicher, E. D. (2020) · Der Diabetologe · doi:10.1007/s11428-020-00606-x · Cited by 4
Webb‐Robertson, B., Nakayasu, E. S., Dong, F., Waugh, K., Flores, J. E., Bramer, L., Schepmoes, A., Gao, Y., Fillmore, T., Önengüt-Gümüşcü, S., et al. (2023) · medRxiv · doi:10.1101/2023.07.13.23292628 · Cited by 4
Self-citationCirculating pancreatic enzyme levels are a causal biomarker of type 1 diabetesPreprint
Elgamal, R. M., Melton, R. L., Chiou, J., McGrail, C., & Gaulton, K. J. (2024) · medRxiv · doi:10.1101/2024.08.08.24311619 · Cited by 4
The Teplizumab Saga: The Challenge of Not Getting Lost in Clinical TranslationPreprint
Chatenoud, L., Herold, K. C., Bach, J., & Bluestone, J. A. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041600 · Cited by 6
Лаптев, Д. Н., Eremina, I. A., Shubina, J., Янкевич, Т. Э., Sechko, E. A., Goncharova, N. A., & Peterkova, V. A. (2024) · Diabetes Mellitus · doi:10.14341/dm13101 · Cited by 3
Paediatric screening in Italy as a gateway to secondary prevention in type 1 diabetes
Messina, M. F., Pozzilli, P., & Zampetti, S. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112233 · Cited by 3
Hipp, H., Tondello, C., Gmehling, H., Scholz, L. K., Stavridou, A., Becker, M., Bührer, A.-M., Hintermann, E., Dirschl, S. M., Johannsmann, T. M., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102218 · Cited by 3
You, L., Salami, F., Tamura, R., Törn, C., Vehik, K., Hagopian, W., Rewers, M., McIndoe, R., Toppari, J., Ziegler, A., et al. (2025) · Pediatric Diabetes · doi:10.1155/pedi/8845330 · Cited by 3
Self-citationHedlund, E., Maziarz, M., Lindahl, T. L., Elding-Larsen, H., Forsander, G., Persson, M., Pundziūtė-Lyckå, A., Åkesson, K., Ludvigsson, J., & Carlsson, A. (2025) · Diabetes Care · doi:10.2337/dc25-0840 · Cited by 3
Twig, G., Simchoni, M., Dym, I., Vinograd, A., Bendor, C. D., Bardugo, A., Tsur, A. M., Zucker, I., Lutski, M., Derazne, E., et al. (2025) · Diabetes Care · doi:10.2337/dc25-1423 · Cited by 3
Majstorovic, M., McGorm, K. J., Wentworth, J. M., Couper, J., & Oxlad, M. (2025) · Diabetic Medicine · doi:10.1111/dme.70178 · Cited by 3
Bombicino, S. S., Trabucchi, A., Sabljic, A. V., Marfía, J. I., Iacono, R. F., & Valdez, S. N. (2025) · European journal of medical research · doi:10.1186/s40001-025-03457-8 · Cited by 3
Fisher, M. S., Philippova, J., Васильевич, К. В., & Sennikov, S. V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311563 · Cited by 4
Veijola, R., Tamura, R., Clasen, J. L., Larsson, H. E., Warncke, K., Steck, A. K., Haller, M. J., Jónsdóttir, B., Akolkar, B., Hagopian, W., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06613-1 · Cited by 3
Self-citationMolecular Portrait of Autoantigens in Type 1 Diabetes
Kandinov, I., Knyazeva, A., Lander, E., Gryadunov, D. A., & Savvateeva, E. N. (2025) · Biomolecules · doi:10.3390/biom15121723 · Cited by 3
Couper, J., Oakey, H., Penno, M. A. S., Wentworth, J. M., Watson, K., Brown, J. D., Huynh, D., Thomson, R. L., Craig, M. E., Davis, E. A., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06591-4 · Cited by 4
Longitudinal monitoring of type 1 diabetes progression to disease onset
King, J. L., Roy, J., Urie, R. R., Bealer, E. J., Crumley, K. M., Rad, L. M., Soleimanpour, S. A., & Shea, L. D. (2026) · Science Advances · doi:10.1126/sciadv.adw8946 · Cited by 4
de Wit, M., Klinker, L. Y., Moore, B., Boggiss, A. L., Allonca, L. F., Asaad, M., Bebbington, K. R., Cleal, B. R., Huisman, S. D., Winterdijk, P., et al. (2026) · Diabetic Medicine · doi:10.1111/dme.70308 · Cited by 3
Ziegler, A., Rewers, M. J., Achenbach, P., Bell, K. J., Bonifacio, E., DiMeglio, L. A., Dutta, S., Larsson, H. E., Frohnert, B. I., Griffin, K., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06841-z · Cited by 4
Self-citationKetoacidosis at diagnosis of type 1 diabetes in children under 15 years of age
Hekkala, A. (2016) · Cited by 3
Pham, V. T., Ciccaglione, M., Ramirez, D. G., & Benninger, R. K. P. (2020) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2022.03.013 · Cited by 3
Successes and Disappointments with Clinical Islet Transplantation
Cravedi, P., Ruggenenti, P. L., & Remuzzi, G. (2013) · Springer eBooks · doi:10.1007/978-94-007-6884-0_23-1 · Cited by 3
Helminen, O., Pokka, T. M.-L., Aspholm, S., Ilonen, J., Simell, O., Knip, M., & Veijola, R. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.972714 · Cited by 3
Self-citationHypothesis: Induction of Autoimmunity in Type 1 Diabetes—A Lipid Focus
Corkey, B. E., Kilpatrick, L. E., & Evans‐Molina, C. (2022) · Diabetes · doi:10.2337/db22-0240 · Cited by 3
Epidemiology and Pathogenesis of Type 1 Diabetes
Stene, L. C., & Lernmark, Å. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_2 · Cited by 3
Extremely Early Appearance of Islet Autoantibodies in Genetically Susceptible Children
Kyrönniemi, A., Valtanen, T., Koskenniemi, J. J., Vähäsalo, P., Härkönen, T., Ilonen, J., Toppari, J., Knip, M., & Veijola, R. (2023) · Pediatric Diabetes · doi:10.1155/2023/9973135 · Cited by 3
Self-citationD’Addio, F., Nasr, M. B., Lunati, M. E., & Fiorina, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00075-8 · Cited by 3
Evaluation of Biochemical Characteristics and Performance of the 3 Screen ICA ELISA Kit
Kawasaki, E., Takahashi, Y., Komeda, T., & Sakuma, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212182 · Cited by 3
Peralta, F. G., Pinés-Corrales, P. J., Santos, E., Cuesta, M., Albarrán, O. G., Azriel, S., Castaño, L. A., Mathieu, C., & on behalf of the AGORA Diabetes Collaborative Group (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020418 · Cited by 4
Lin, T.-C., Lacorcia, M., & Mannering, S. I. (2025) · Biomolecules · doi:10.3390/biom15030384 · Cited by 3
Lacorcia, M., Bhattacharjee, P., Foster, A., Hardy, M. Y., Tye–Din, J. A., Karas, J. A., Wentworth, J. M., Cameron, F. J., & Mannering, S. I. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adt2124 · Cited by 3
Metadata
- Authors
- Ziegler, A. G., Rewers, M., Simell, O., Simell, T., Lempainen, J., Steck, A., Winkler, C., Ilonen, J., Veijola, R., Knip, M., Bonifacio, E., & Eisenbarth, G. S.
- Affiliations
- TUM Klinikum (DE)
- University of Helsinki (FI)
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-06-19
- Volume
- 309
- Issue
- 23
- Pages
- 2473
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC4878912
- OpenAlex
- W2095256598
- Semantic Scholar
- 5a7a8cb24a1d4a727e23b19c717a8328b3ce09d6
- Cited by
- 1,312
- References
- 29
- Citations by year
- 2026: 118 · 2025: 133 · 2024: 103 · 2023: 124 · 2022: 107 · 2021: 127 · 2020: 83 · 2019: 92 · 2018: 92 · 2017: 86 · 2016: 89 · 2015: 83 · 2014: 55 · 2013: 18
- FWCI
- 54.19
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion)
- Funders
- Juvenile Diabetes Research Foundation International (4‐1999‐731, 4‐2001‐435)
- Deutsche Forschungsgemeinschaft (/14-2, /14-1)
- Bundesministerium für Bildung und Forschung
- Novo Nordisk
- Lastentautien Tutkimussäätiö
- National Institutes of Health (DK32493)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK32493, R01DK032493, U01DK063821)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 1 diabetes, islet autoantibodies, seroconversion, multiple autoantibodies, progression to diabetes, insulin autoantibodies, GAD65 antibodies, IA-2 autoantibodies, preclinical diabetes, risk prediction, age at seroconversion, islet transplantation
- MeSH terms
- Adolescent, Autoantibodies, Child, Child, Preschool, Colorado, Diabetes Mellitus, Type 1, Female, Finland, Follow-Up Studies, Genotype, Germany, Glutamate Decarboxylase, Humans, Infant, Insulin, Islets of Langerhans, Male, Prospective Studies, Risk, Disease Progression, Genetic Predisposition to Disease, Receptor-Like Protein Tyrosine Phosphatases, Class 8
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
